Transient receptor potential (TRP) ion channels constitute a 28-member family mainly composed of outwardly rectifying, nonselective cation channels and are commonly considered to be detectors and transducers of sensory stimuli (1). TRP Ankyrin 1 (TRPA1) represents the lone member of the TRPA subfamily within mammals (2) . Although primarily associated with nociception (3, 4) , TRPA1 also influences physiological functions other than pain sensing (5) .
TRPA1 is primarily considered a chemosensor; it has a long list of endogenous and exogenous agonists and antagonists (1, 2). The agonists can be divided into either electrophilic or non-electrophilic modulators (6) . Interestingly some general anesthetics are TRPA1 nonelectrophilic agonists, resulting in paradoxical pronociceptive effects (7) (8) (9) (10) . For example, propofol ( Figure  1A ), the most commonly used intravenous general anesthetic, shows a bimodal activity on TRPA1; activating at low concentration and blocking at high (7, 9) . Studies have shown that TRPA1 is the major player in propofol's algogenic properties, as well as a potential contributor to post-operative pain and propofol-induced vasodilation (7, 11) . As our understanding of the channel's physiological functions improves, it becomes progressively clearer that the activation/inhibition of TRPA1 may also influence other aspects of propofol pharmacology including those that may directly underlie components of anesthesia.
Uncovering the propofol modulatory site(s) will further our understanding of the TRPA1 molecular machinery and physiological functions as well as provide information for drug design. Ton et al. identified a series of mutations (S876V, S876V/T877L, M915L or M956A/V) that eradicated propofol activation of rat TRPA1 (12) . These studies suggested a binding cavity, common with the TRPA1 antagonist A-967079 site (12, 13) , as an allosteric site for propofol modulation. However site-directed mutagenesis cannot definitively distinguish ligand binding sites from confounding alterations in the protein's dynamics. Therefore more direct approaches are needed to reveal the propofol binding site(s) in TRPA1. We used photoaffinity labeling, using a photoactive derivative of propofol called meta-azipropofol (AziPm; Figure 1A ) (14) to provide direct evidence for alkylphenol-based anesthetic binding sites within heterogously expressed mouse TRPA1.
To allow for photoreactivity, modifications within the propofol chemical structure were required (14) . AziPm contains a trifluorodiazirine at the meta-position that upon UV irradiation generates a singlet carbene, a highly reactive and photochemically nonselective species (15, 16) . As a result, AziPm provides for unbiased labeling of binding sites. However, given the differences in their chemical structures, we first aimed to verify that AziPm demonstrated similar TRPA1 activity as compared to the parent anesthetic propofol. To accomplish this we measured activation of C-terminally tagged mouse TRPA1 (mTRPA1-FLAG) expressed baculovirus-infected Sf21 insect cells using a Fura-2 based bulk calcium influx assay. Both propofol and AziPm significantly activated mTRPA1 channels within concentration ranges similar to those used for propofol in previous reports (see Fig. S1 ) (7, 9, 12) . The responses to both propofol and AziPm were specific to mTRPA1 as neither caused calcium influx in rat TRP vanilloid 1 (rTRPV1)-expressing or empty-vector baculovirus-infected Sf21 cells (see Fig. S1 ). mTRPA1-FLAG activation was concentration dependent (see Fig. S1 ) with EC 50 values of 17 µM (11.7-25 .0 µM; CI 95%) and 8.1 µM (3.18-26.1 µM; CI 95%) for propofol and AziPm respectively (see Supporting Materials and Methods). The activating concentrations are considered clinically relevant (0.3-60 µM) (17, 18) and are comparable to other established protein targets like GABA A receptors (19). Also similar to previous reports, both propofol and AziPm exhibited bimodal effects, with reduced activation at the highest concentration examined (see Fig. S1 ) (7, 9) . In summary, the similar modulatory behavior of both propofol and the photoaffinity derivative AziPm likely reflect shared TRPA1 binding site(s).
Next we sought to determine whether the similar TRPA1 functional activity displayed by AziPm was via common binding site(s) with propofol. To this end, isolated membranes containing mTRPA1-FLAG were photolabeled with tritiated AziPm ([ 3 H]AziPm) in the presence or absence of propofol. After photolabeling, channels were purified using anti-FLAG resin and SDS-PAGE electrophoresis. We then determined whether the propofol inhibited, or 'protected', (15) (Fig. 1B) , similar to what has been observed within other known propofol targets (15, 16) , including the GABA A receptor (19). Therefore, the result is consistent with our functional results that suggested common binding site(s) and molecular mechanism.
We next identified the mTRPA1-FLAG residues photolabeled with AziPm by mass spectrometry (MS) microsequencing. After photolabeling isolated membranes containing mTRPA1-FLAG, we purified the channels using anti-FLAG resin and SDS-PAGE electrophoresis followed by in-gel sequential trypsin and chymotrypsin digestion. MS analysis resulted in ~93% sequence coverage (see Fig.  S2 ) two residues with the AziPm photomodification were detected: V954 and E969 ( Figure 2C , see Fig S3-4) . Both residues are located within a highly conserved region of the TRPA1 S6 helix in the TMD and are identical for both mTRPA1 and human TRPA1 (hTRPA1; Figure 2D ). S6, along with S5, forms the channel gate within 6TM-channels; therefore it is not surprising that ligand binding near S6 influences the dynamics and activity of 6TM-channels (20, 21). Interestingly these residues do not share identity within the propofol insensitive Drosophila TRPA1 (9, 12) , again suggesting that these residues may contribute to functionally relevant propofol binding site(s) ( Figure  2D ). Of note, the two residues are not exposed to a shared cavity; the structure instead suggests that each label corresponds to a distinct binding site on TRPA1.
To further clarify the propofol and AziPm binding cavities that contribute to the altered activity, we generated models of hTRPA1 in the closed state (model- Fig. S5 ). The photolabeled residues V954 and E969 in mTRPA1-FLAG align with V951 and E966 respectively in hTRPA1 ( Figure 2D ). E966 is located near the end of the S6 helix below the lower hydrophobic gate defined by I957 and V961. Within model-2 the S6 helices adopt a 'bend and twist' conformation in comparison to the cryo-EM structure, an anticipated common conformational change for opening of 6TM-channels (23, 24), which orients E966 more fully into pore (Fig 2D-E) . Given the location of the photolabeled residue respective to the lower hydrophobic gate and putative open state model, we anticipate that the E969 photolabeling in mTRPA1-FLAG by AziPm is indicative of an activation-dependent pore block site. Indeed propofol and AziPm both displayed similar bimodal activity (see Fig S1) and propofol has been reported to display a 'surge' response during drug wash out, characteristic of pore block inhibition (7, 9) .
Within model-1 and model-2, V951 is located on the S6 helix near two previously reported ligand binding pockets within TRP channels (2): the S4-S5 pocket, analogous to the resiniferatoxin binding site in rat TRPV1 (24), and the S5-S6 pocket containing the antagonist A-967079 site (13) . Model-1 orients V951 facing the S4-S5 linker and therefore accessible to both pockets while the conformation adopted in model-2 orients the residue further into the S5-S6 pocket (Fig. 2B-C) . We performed docking experiments using AutoDockVina (25) and set a docking region that included both cavities to elucidate whether propofol and AziPm would be capable of occupying either pocket. The results indicated that for both models the S4-S5 and S5-S6 pockets could accommodate either ligand with poses represented in either site. For both model-1 and model-2 the highest scored and the majority of docking poses were located within the S5-S6 pocket near the A-967079 binding site (13) and in close proximity to the V951 (Fig. 2B-C) . Recently it has been shown that mutating S876, S876/T877, M915 or M956 in mTRPA1 selectively abolishes propofol activation of the channel (12) . These residues align with S873, T874, M912, and M953 in hTRPA1 and indicated a propofol allosteric site within the S5-S6 pocket. Our results showing the photolabeling of V954 in mTRPA1 by AziPm confirms a likely positive modulatory anesthetic binding site within the TRPA1 TMD and further suggests the S5-S6 as an activation site for propofol.
Cumulatively our results suggest that: (i) propofol activation of TRPA1 is through a higher affinity binding site located within TMD cavities associated with the S6 helix, likely within the S5-S6 pocket, and (ii) propofol inhibition of TRPA1 at higher concentrations is by activation-dependent pore block, likely proximal to E969. Together these mechanisms would be predicted to result in the observed bimodal TRPA1 activity. Given the lack of current structural knowledge, specifically on the open state channel, determining an exact molecular mechanism is a challenge. To glean insights into the molecular determinants of such state-dependent binding of propofol, we generated a model of TRPA1 open state using the cryo-EM structure of TRPV1 as template. Due to the uncertainties inherent to comparative homology modeling, we regard the resulting structural information as hypothetical. Within these limitations, docking simulations show that, in the open state, V951 and E969 are oriented toward a potential positive modulatory site and the conduction pore, respectively, thereby providing a tentative explanation for the dual effect of propofol.
Two complementary but distinct approaches, mutagenesis (12) and photolabeling studies described here, suggest a propofol activation site located within the S5-S6 pocket of TRPA1. Additionally, our current and other previous investigations show that propofol, at high concentrations, has functional activity that is characteristic of non-specific pore block (7, 9) . Our study provides additional support for this mechanism by the identification of a second photolabeled site within the TRPA1 pore.
Each approach has limitations. Photolabeling requires a modified ligand and the inability to link each site to a specific functional role. Mutagenesis alone often results in ambiguity because of changes to protein dynamics and energetics unrelated to ligand binding. Taken together, however, our methods and results directly identify alkylphenol-based general anesthetic binding sites on TRPA1 receptors that rationally explain both activation and inhibition of ion channel activity, and that furthers our understanding of the pharmacology of these commonly used drugs. 
SUPPORTING MATERIAL

SUPPORTING METHODS
Cloning and Expression. Silent mutations a660c and t2163c were introduced into the mouse TRPA1 cDNA (provided by Ardem Patapoutian) to remove two NdeI sites. Full-length TRPA1 was amplified by PCR and ligated between the NdeI and NotI sites of a modified pFastBac1 vector, pFastBac-CFlag, introducing a C-terminal trialanine linker followed by a FLAGtag (AAADYKDDDDK). Rat TRPV1 baculovirus is previously described 1 . Baculoviruses were generated and used according to standard Bac-to-Bac protocols (Thermo Fischer Scientific, Waltham, MA). Mutants were generated by Quikchange mutagenesis protocol (Stratagene) and all clones were verified by DNA sequencing. Sf21 cells were grown at 27°C in Hink's TNM-FH medium (Mediatech, Manassas, VA) supplemented with 10% fetal bovine serum and 10 µg/mL gentamicin.
Membrane preparation . Sf21 cells (66 mL at 1.25 x 10 6 cells/mL) were infected with mTRPA1-FLAG baculovirus and harvested 48 h post-infection, frozen in liquid nitrogen and stored at -80°C. Membranes were prepared at 4°C. Cells were resuspended and homogenized in 3.5 mL lysis buffer (20 mM HEPES, pH 7.2, 1X Halt Protease Inhibitor Cocktail (Thermo Scientific, Waltham, MA)). Successful lysis was confirmed by visualizing cells under light microscope using Trypan Blue. The homogenate was centrifuged 15 min at 1000 x g. The cleared supernatant was centrifuged at 55000 RPM in a Ti90 rotor (Beckman-Coulter, Brea, CA) for 45 min, and the resulting membrane pellets resuspended at 1 mg/mL total protein in lysis buffer and stored in 50 µL aliquots at -80°C. Immunopurification of TRPA1-FLAG channels . Irradiated membrane preparations were diluted to 0.25 mg/mL with a final concentration of 6.25 mM n-dodecyl-β-D-maltoside (DDM) in buffer A containing protease and phosphatase inhibitors. Membranes were solubilized by gentle rocking for 4 hr, in the dark, at 4 °C. These samples were diluted to 0.1 mg/mL and a final DDM concentration of 2.5 mM with buffer A containing protease and phosphatase inhibitors equilibrated for 2 hrs, in the dark, at 4°C before centrifugation at 16,000 x g for 20 min at 4°C to remove insoluble debris. ANTI-FLAG M2 Affinity Gel (Sigma) was equilibrated with one wash of buffer A without sucrose, then two washes of buffer A, and finally two washes of buffer A containing 2.5 mM DDM, 20 resin volumes each. Equilibrated 20 µL ANTI-FLAG ® M2 Affinity Gel was added to each solubilized membrane preparation. Samples were incubated in the dark overnight with gentle over-end mixing at 4°C. The resin was washed three times with 20 volumes of buffer A containing 75 µM DDM. TRPA1-FLAG was eluted from resin by the addition of 2X SDS buffer before separation by SDS-PAGE. Gels were stained with Coomassie blue G-250, destained, and thoroughly washed with ddH 2 O.
Scintillation counting-Gels were scanned on a Bio-Rad GS-800 calibrated densitometer with quantitation performed using the accompanying Quantity One software. Background was subtracted with a box drawn between the 100-and 150-kDa molecular mass markers, and mean optical density multiplied by band area was recorded from excised band regions. Excised bands were placed into scintillation vials containing 1 mL of 30% hydrogen peroxide and incubated overnight at 65°C to dissolve the polyacrylamide. Samples were cooled to room temperature before adding 10 mL EcoLite(+) liquid scintillation mixture (MP Biomedicals). Samples were analyzed using PerkinElmer Life Sciences Tri-Carb 2800TR instrument.
In-gel protease digestion. Identified protein bands at ~110-140kDa, corresponding to TRPA1-FLAG, were excised, destained, dehydrated and dried by SpeedVac before proteins were reduced by incubation at 56°C for 20 min in 25 mM dithiothreitol (DTT) and 50 mM NH 4 HCO 3 . The DTT solution was removed and proteins were then alkylated by the addition of 55 mM iodoacetamide in 50 mM NH 4 HCO 3 and incubation at room temperature in the dark. Bands were dehydrated and dried by SpeedVac before resuspension in 100 μL 0.2 % ProteaseMAX™ Durfactant (Promega), 1 mM CaCl 2 and 50 mM NH 4 HCO 3 solution containing sequencing grade trypsin (Promega) at a 1:20 protease:protein ratio (w/w). Proteins were digested overnight at 37°C. After, samples were diluted to 200 μL with final concentration of 100 mM NH 4 HCO 3 and 0.2% ProteaseMAX™ Surfactant prior to the addition of sequencing grade chymotrypsin (Promega) to a final 1:20 protease:protein ratio (w/w). Proteins were digested overnight at 37°C. To increase hydrophobic peptide retrieval from the gel, multiple peptide extractions were performed. First the initial peptide digest solution was removed and 100 μL 30% acetylnitrile (ACN) and 5% acetic acid in ddH 2 O (v/v%) was added. Samples were sonicated for 20 min. The second peptide extraction was removed before 100 μL 70% ACN and 5% acetic acid in ddH 2 O (v/v%) was added. Samples were sonicated for 20 min. All peptide digests were pooled and dried by SpeedVac before resuspension in 0.5% acetic acid and desalting using C18 stage tips prepared in house. Samples were dried by SpeedVac and resuspended in 0.1% formic acid immediately prior to mass spectrometry analysis.
Mass spectrometry. Desalted peptides were analyzed on an Orbitrap Elite TM Hybrid Ion Trap-Orbitrap Mass Spectrometer (MS) coupled to an Easy-nanoLC 1000 system with a flow rate of 300 nL/min. Peptides were eluted with 100 min with linear gradients of ACN in 0.1% formic acid in water (v/v) starting from 2% to 40% (85 min), then 40% to 85% (5 min) and finally 85% (10 min). Data dependent acquisition mode was applied with a dynamic exclusion of 45 s. In every 3 s cycle, one full MS scan was collected with a scan range of 350 to 1500 m/z, a resolution of 60K and a maximum injection time was 50 ms and automatic gain (AG) control of 500000. The MS2 scans were followed from the most intense parent ions. Ions were filtered with charge 2-5 with an isolation window of 1.5 m/z in quadruple isolation mode. Ions were fragmented using collision induced dissociation (CID) with collision energy of 35%. Iontrap detection was used with normal scan range mode and rapid iontrap scan rate. AG was set to be 10000 with a maximal injection time of 100 ms.
Mass spectrometry analysis. Spectral analysis was conducted using Thermo Proteome Discoverer 2.0 (Thermo Scientific) and the Mascot Daemon search engine using a customized database containing mTRPA1-AAA-FLAG sequences supplied for heterologous expression. All analyses included dynamic oxidation of methionine (+15.9949 m/z) and static alkylation of cysteine (+57.0215 m/z; iodoacetamide alkylation). Photolabeled samples were run with the additional dynamic AziPm (+216.1996 m/z) modification. A mass variation tolerance of 10 ppm for MS and 0.8 Da for MS/MS were used. The in-gel sequential trypsin/chymotrypsin digests were searched without enzyme specification with a false discovery rate of 0.01%. Samples were conducted in triplicate and samples containing no photoaffinity ligand were treated similarly to control for false positive detection of photoaffinity ligand modifications. . For model-1, the templates were taken from the cryo-electron microscopy structures for human TRPA1 (PDB ID: 3J9P) 2 and TRPV1 (PDB ID: 5IRX) 6 . A multiple sequence alignment containing the templates and the full-length sequence of human TRPA1 (UniProt code: O75762) was generated using PROMALS3D 7 and EMBOSS 8 . We then generated a pool of 6032 models and selected the most representative one by combining multiple criteria: clustering (choosing the central structure of the most populated clusters), DOPE score (lowest values) and visual inspection. We then optimized the rotameric state of all the side chains using SCWRL4 5 . For model-2, we adopted an analogous protocol, except for the templates: in this case we used the structure of the open state of TRPV1 (PDB ID: 5IRX) and limited the model to the transmembrane region. We generated an initial pool of 500 models and the top structure was selected and optimized as described above. Docking. Generated model-1 and model-2 for TRPA1 were used for docking experiments. Ions and crystallographic ligands were removed by PyMOL 9 . AutodockTools4 10 was used to add hydrogens and Kollman charges, merge nonpolar hydrogen, and define flexible residues. Molecular coordinates for propofol were downloaded from the ZINC small molecule library 11 using provided physical representations. The molecular coordinates for AziPm were generated using MarvinSketch version 16.3.28.0 and AutodockTools4 to generate geisteiger charges and to merge nonpolar hydrogens. The maximum torsions were allowed for propofol and AziPm respectively (i.e., ligands were fully flexible). Separate docking simulations using AutoDock Vina 12 were performed similar to as previously reported 13, 14 of the entire accessible TMD interface cavities formed by three TRPA1 monomers. The grid box dimensions were 32x28x32 for model-1 and 32x26x32 model-2 at 1Å resolution and contained both S4-S5 15 and S5-S6 pockets (A-967079 binding site) 2 as well as the width of the TMD region. All cavity facing residue side-chains were made flexible. Images and distance measurements were prepared using PyMOL.
Statistics. GraphPad Prism 7 or Microsoft Excel was used for preparation of graphs and statistical analysis. All p-values are reported in the figures and figure legends, as appropriate. 
